ReviewExpert review of molecular diagnostics2012
The cellular origin for malignant glioma and prospects for clinical advancements.
Review in Expert review of molecular diagnostics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 217 citations in OpenAlex.
- Review
- The Gut-Brain-Immune Axis in Glioma: Emerging Mechanisms and Therapeutic Opportunities.Cellular and molecular neurobiology · 2026Review
- Single-nucleus transcriptomics identifies cell cycle and synaptic pathway dysregulation during OPC-to-glioma progression.Frontiers in cellular neuroscience · 2026Article
- Recent Advancements in Nanoparticles-based Approaches for the Theranostics of Glioblastoma Multiforme.Current pharmaceutical biotechnology · 2026Review
- GPR55 and PINK1 as emerging therapeutic targets in Glioma: insights into their modulation by phytochemicals and plant extracts.Frontiers in pharmacology · 2026Review
- Radiotherapy-associated changes in the miR-124/SP1 axis in a rat glioma model.Iranian journal of basic medical sciences · 2026Article
- Glia Preserve Their Own Functions While Compensating for Neighboring Glial Cell Dysfunction.Glia · 2025Article
- IL-1βJournal of neuroinflammation · 2025Article
- Review
- Towards Optical Biopsy in Glioma Surgery.International journal of molecular sciences · 2025Review
- Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions.Cells · 2025Review
- The Frequency of a Magnetic Field Determines the Behavior of Tumor and Non-Tumor Nerve Cell Models.International journal of molecular sciences · 2025Article
- Response Assessment in Long-Term Glioblastoma Survivors Using a Multiparametric MRI-Based Prediction Model.Brain sciences · 2025Article
- Blood-derived APLP1Science advances · 2025Article
- Glioma-neuron interactions: insights from neural plasticity.Frontiers in oncology · 2025Review
- Deciphering the topological landscape of glioma using a network theory framework.Scientific reports · 2024Article
- Macrophage polarization-related gene signature for risk stratification and prognosis of survival in gliomas.Journal of cellular and molecular medicine · 2024Article
- Understanding the Role of Endothelial Cells in Glioblastoma: Mechanisms and Novel Treatments.International journal of molecular sciences · 2024Review
- Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches.International journal of molecular sciences · 2024Review
- Deciphering the role of transcription factors in glioblastoma cancer stem cells.Acta biochimica et biophysica Sinica · 2024Review
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Glioma remains incurable despite great advancements in medicine. Targeting the cell of origin for gliomas could bring great hope for patients. However, as a collection of diverse diseases, each subtype of glioma could derive from a distinct cell of origin. To resolve such a complex problem, one must use multiple research approaches to gain deep insights. Here we review current evidence regarding the cell of origin from clinical observations, whole-genome molecular pathology and glioma animal models. We conclude that neural stem cells, glial progenitors (including oligodendrocyte progenitor cells) and astrocytes could all serve as cells of origin for gliomas, and that cells incurring initial mutations (cells of mutation) might not transform, while their progeny cells could instead transform and act as cells of origin. Further studies with multidisciplinary approaches are needed to link each subtype to a particular cell of origin, and to develop effective therapies that target the signaling network within these cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.